Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

FDA expands age indication of Adacel vaccine for immunization against tetanus, diphtheria, pertussis

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of AdacelĀ® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 10 through 64 years of age. [More]
Novel proteins may lead to new ways to combat venereal disease

Novel proteins may lead to new ways to combat venereal disease

Researchers at Oregon State University have discovered novel proteins in, or on the surface of the bacteria that causes gonorrhea, which offer a promising new avenue of attack against a venereal disease that is showing increased resistance to the antibiotics used to treat it. [More]
Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children. [More]

New urinary catheter design can eliminate nearly all hard-to-kill biofilm

For the millions of people forced to rely on a plastic tube to eliminate their urine, developing an infection is nearly a 100 percent guarantee after just four weeks. But with the help of a little bubble-blowing, biomedical engineers hope to bring relief to urethras everywhere. [More]

Researchers evaluate influence of gut microbes on function of immune cells

New research suggests that gut microorganisms do not merely influence immune cell function, but also support the production of immune cells that form the first line of defense against infection. [More]

Researchers decode effects of antimicrobial peptide on bacterial cells

The team of Julia Bandow, who heads the RUB's Junior Research Group Microbial Antibiotic Research, has been studying the MP196 peptide as a representative of a group of very small positively charged peptides that consist of some four to ten amino acids. [More]
Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. [More]
Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

Emergence of community-acquired infections due to ESBL-producing bacteria on the rise

The emergence of community-acquired infections, such as urinary tract infections (UTI), due to strains resistant to common antibiotics are on the rise, according to Rhode Island Hospital researchers. The study is published online in the journal Antimicrobial Resistance and Infection Control. [More]
ASU scientist selected as 2014 recipient of Lifetime Achievement Award

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology. [More]
SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS. [More]
Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown. [More]

Antibiotics for UTI often taken before, after incontinence surgery

One in four women undergoing surgery for urinary incontinence has recently taken antibiotics for a urinary tract infection, a large population-based study shows. [More]
CSP analogues may attenuate S. pneumoniae virulence, resistance

CSP analogues may attenuate S. pneumoniae virulence, resistance

The spread of virulent, antibiotic-resistant strains of Streptococcus pneumoniae may be controllable through the use of competence-stimulating peptide analogues, US researchers believe. [More]
Breastfeeding increases prevalence of Lactobacilli and Bifidobacteria in infants

Breastfeeding increases prevalence of Lactobacilli and Bifidobacteria in infants

Breastfeeding until at least nine months of age increases prevalence in the gastrointestinal tract of Lactobacilli and Bifidobacteria, species which are known to contribute to development of a healthy immune system, according to a paper describing the establishment of the intestinal microbiota during the first three years of life. [More]
Researchers developing new medication to tackle river blindness and elephantiasis

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world. [More]

Scientists produce antibiotic whose biological activity can be controlled with light

Scientists of the KIT and the University of Kiev have produced an antibiotic, whose biological activity can be controlled with light. Thanks to the robust diarylethene photoswitch, the antimicrobial effect of the peptide mimetic can be applied in a spatially and temporally specific manner. [More]

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013. [More]

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE (Investigating Gram-negative Infections Treated with Eravacycline). [More]
New study provides first ever reliable data on antibiotic use in non-EU countries

New study provides first ever reliable data on antibiotic use in non-EU countries

A new study, published in The Lancet Infectious Diseases journal, provides the first ever reliable data on antibiotic use in non-European Union southern and eastern European countries and newly independent states. [More]

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis. [More]